Patent ID: 7815921

Claim:
A method for predicting the risk of diseases, disorders or complications associated with cytotoxic therapy and/or hematopoietic cell transplantation in a subject comprising the step of: (a) identifying a subject with multiple myeloma or lymphoma that has received cytotoxic therapy comprising chemotherapy; (b) administering to the subject a single dose of G-CSF sufficient to allow mobilization or release of the leukocytes from hematopoietic production and storage tissue and sites of migration into the blood of the subject; and (c) determining whether the subject has high, medium or low hematopoietic cytocapacity; wherein a subject with a high hematopoietic cytocapacity indicates a reduced risk of disease, disorder, or complications associated with cytotoxic therapy and/or hematopoietic cell transplantation relative to a subject with low or medium hematopoietic cytocapacity, wherein the disease, disorder, or complications are selected from fever greater than 38° C., severity and duration of neutropenia, duration of leucopenia, infection, duration of i.v. antibiotic treatment, time for platelet recovery, or time for neutrophil recovery.